Researchers ask whether the GLP-1 era is reviving diet culture and eating disorders
Northeastern University clinicians warn that widespread GLP-1 use may be reviving diet culture and raising eating-disorder risk, especially for younger users and people with a history of restriction.
A commentary from clinicians at Northeastern University's Bouvé College of Health Sciences argues that the mainstreaming of GLP-1 weight-loss drugs like Mounjaro and Ozempic has pulled explicit diet culture back into everyday conversation, and that this shift could raise the risk of disordered eating for some people [1]. The piece, published August 19, 2026, is expert commentary rather than new clinical data, but it lands alongside a wave of August 2026 analyses arguing that obesity medicine and eating disorder care can no longer be treated as separate fields [1].
Professor Ashleigh Shields, who studies eating disorders and has spoken publicly about her own history with disordered eating, told Northeastern Global News that "every generation kind of has these magic diet pills," pointing to past examples like fen-phen, which led to a $3.75 billion class-action settlement over serious complications, and ephedra supplements, which are now banned by the FDA [1]. She said GLP-1s are different because they are legitimate, FDA-approved medicines and a "godsend" for people who need them, but she warned that "people are rushing to do these things without really thinking about or understanding the consequences" [1].
The scale of eating disorders in the US is large. The National Eating Disorders Association (NEDA) estimates that 9 percent of the US population, roughly 31 million Americans, has experienced an eating disorder at some point in life, and that a person dies as a direct consequence of an eating disorder every 52 minutes [1]. NEDA says the full effect of drugs like Ozempic on eating disorders is not yet known, but the organization urges caution around GLP-1 use for people at elevated risk, citing recent research and anecdotal reports of misuse [1].
Author Alexis Conason, who wrote "The Diet-Free Revolution," told Northeastern Global News that before the GLP-1 era there was more cultural pushback against diet mentality, with an emphasis on the idea that bodies of different sizes could be equally healthy [1]. She said GLP-1s have flipped that narrative: because weight now appears controllable through medication, thinness can look like a matter of personal responsibility again [1]. Shields connected this to a broader return of thinner beauty standards, describing a resurgence of "heroin chic" aesthetics now rebranded as "Ozempic body" [1].
Shields also pointed to a specific mechanism of risk for people actually taking the drugs. She said that in her own research before GLP-1s existed, she found that weight-loss efforts can take on a life of their own, with people feeling that a set goal is "never enough" once reached [1]. She said GLP-1-driven weight loss, because it can happen quickly and with less visible effort, may add extra momentum to that pattern, particularly since tolerance to the drugs can build over time and lead to regaining lost weight, which she said can leave people vulnerable to disordered eating [1].
Why it matters for patients
The commentary does not present new trial data or claim that GLP-1 drugs themselves cause eating disorders. It argues instead that the surrounding culture, celebrity weight-loss stories, and renewed emphasis on thinness may increase psychological risk for people who already have a history of restriction or are otherwise vulnerable, especially younger users [1]. NEDA's own position is that the science on GLP-1s and eating disorders is still incomplete, even as the group urges caution for at-risk groups [1]. For patients already managing an eating disorder history, or supporting someone who is, this is a reminder that the conversation around these drugs extends beyond physical side effects into mental health and body image, an area the sources say is not yet fully studied [1].
What happens next
The Northeastern piece is part of what it describes as a broader wave of analyses published in August 2026 arguing that obesity medicine and eating disorder treatment should be integrated rather than kept as separate specialties [1]. No specific dated clinical studies, regulatory actions, or new NEDA guidance are cited in the source beyond its general caution about GLP-1 use, so how this debate will translate into formal treatment guidelines or research remains unknown from the available reporting [1].
Sources
Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.